Compare ITI Pharma and Healthcare Fund vs SBI Healthcare Opportunities Fund
Risk | Very High | Very High |
Rating | 2.0 | 5.0 |
Min SIP Amount | ₹500 | ₹500 |
Expense Ratio | 2.35 | 1.93 |
NAV | ₹15.64 | ₹422.25 |
Fund Started | 18 Oct 2021 | 04 Jun 1999 |
Fund Size | ₹230.85 Cr | ₹4130.76 Cr |
Exit Load | Exit load of 0.50%, if redeemed within 3 months. | Exit load of 0.50% if redeemed within 15 days |
Risk
Very High
Very High
Rating
2.0
5.0
Min SIP Amount
₹500
₹500
Expense Ratio
2.35
1.93
NAV
₹15.64
₹422.25
Fund Started
18 Oct 2021
04 Jun 1999
Fund Size
₹230.85 Cr
₹4130.76 Cr
Exit Load
Exit load of 0.50%, if redeemed within 3 months.
Exit load of 0.50% if redeemed within 15 days
1 Year | -7.85% | -1.09% |
3 Year | 18.83% | 23.81% |
5 Year | - | 16.93% |
1 Year
-7.85%
-1.09%
3 Year
18.83%
23.81%
5 Year
-
16.93%
Equity | 97.29% | 95.82% |
Cash | 2.71% | 4.11% |
Equity
97.29%
95.82%
Cash
2.71%
4.11%
Top 10 Holdings |
|
|
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 12.73% |
Divi's Laboratories Ltd. | 8.75% |
Apollo Hospitals Enterprise Ltd. | 6.12% |
Max Healthcare Institute Ltd. | 6.08% |
Torrent Pharmaceuticals Ltd. | 4.26% |
Aurobindo Pharma Ltd. | 4.02% |
Fortis Healthcare Ltd. | 3.60% |
Cohance Lifesciences Ltd. | 3.58% |
Lupin Ltd. | 3.25% |
Aster DM Healthcare Ltd. | 3.09% |
Sun Pharmaceutical Industries Ltd. | 11.97% |
Divi's Laboratories Ltd. | 6.90% |
Max Healthcare Institute Ltd. | 5.63% |
Cipla Ltd. | 4.45% |
Lupin Ltd. | 4.23% |
Lonza Group Ag | 4.01% |
Acutaas Chemicals Ltd. | 4.00% |
Torrent Pharmaceuticals Ltd. | 3.60% |
Laurus Labs Ltd. | 3.50% |
Fortis Healthcare Ltd. | 3.34% |
Name | Dhimant Shah | Tanmaya Desai |
Start Date | 06 Feb 2025 | 17 May 2024 |
Name
Dhimant Shah
Tanmaya Desai
Start Date
06 Feb 2025
17 May 2024
Description | The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 18 Oct 2021 | 04 Jun 1999 |
Description
The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare.
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Launch Date
18 Oct 2021
04 Jun 1999